Coronavirus: Need for a therapeutic approach

The Lancet Infectious Diseases

Volumn 13, Issue 9, 2013, Pages 726-727

  Guery, Benoit ^a   van der Werf, Sylvie ^b  

^a LILLE UNIVERSITY HOSPITAL   (France)

^b INSTITUT PASTEUR   (France)

Author keywords

[No Author keywords available]

Indexed keywords

ALPHA INTERFERON;

CORONAVIRUS; CORONAVIRUS INFECTION; HUMAN; LETTER; MIDDLE EAST RESPIRATORY SYNDROME CORONAVIRUS INFECTION; MULTIPLE ORGAN FAILURE; PRIORITY JOURNAL; SEPTIC SHOCK; SEVERE ACUTE RESPIRATORY SYNDROME; VIRUS LOAD; VIRUS SHEDDING;

CORONAVIRUS; CORONAVIRUS INFECTIONS; GENOME, VIRAL; HUMANS; MALE; RNA, VIRAL;

EID: 84882620006     PISSN: 14733099     EISSN: 14744457     Source Type: Journal    
DOI: 10.1016/S1473-3099(13)70153-1     Document Type: Letter

References (13)

1. Peiris JSM, Guan Y, Yuen KY Severe acute respiratory syndrome. Nat Med 2004, 10:S88-S97.
2. Stockman LJ, Bellamy R, Garner P SARS: systematic review of treatment effects. PLoS Med 2006, 3:e343.
3. Zaki AM, van Boheemen S, Bestebroer TM, Osterhaus ADME, Fouchier RAM Isolation of a novel coronavirus from a man with pneumonia in Saudi Arabia. N Engl J Med 2012, 367:1814-1820.
4. Bermingham A, Chand MA, Brown CS, et al. Severe respiratory illness caused by a novel coronavirus, in a patient transferred to the United Kingdom from the Middle East, September 2012. Euro Surveill 2012, 17:20290.
5. Memish ZA, Zumla AI, Al-Hakeem RF, Al-Rabeeah AA, Stephens GM Family cluster of Middle East Respiratory Syndrome coronavirus infections. N Engl J Med 2013, published online May 29. 10.1056/NEJMoa1303729.
6. Pebody RG, Chand MA, Thomas HL, et al. The United Kingdom public health response to an imported laboratory confirmed case of a novel coronavirus in September 2012. Euro Surveill 2012, 17:20292.
7. Guery B, Poissy J, Mansouf El L, et al. Clinical features and viral diagnosis of two cases of infection with Middle East Respiratory Syndrome coronavirus: a report of nosocomial transmission. Lancet 2013, published online May 30. http://dx.doi.org/10.1016/S0140-6736(13)60982-4.
8. Drosten C, Seilmaier M, Corman VM, et al. Clinical features and virological analysis of a case of Middle East respiratory syndrome coronavirus infection. Lancet Infect Dis 2013, published online June 17. http://dx.doi.org/10.1016/S1473-3099(13)70154-3.
9. Josset L, Menachery VD, Gralinski LE, et al. Cell host response to infection with novel human coronavirus EMC predicts potential antivirals and important differences with SARS coronavirus. MBio 2013, 4:e00165. e00113.
10. de Wilde AH, Ray VS, Oudshoorn D, et al. Human coronavirus-EMC replication induces severe in vitro cytopathology and is strongly inhibited by cyclosporin A or interferon-alpha treatment. J Gen Virol 2013, published online April 25. 10.1099/vir.0.052910-0.
11. Falzarano D, de Wit E, Martellaro C, Callison J, Munster VJ, Feldmann H Inhibition of novel β coronavirus replication by a combination of interferon-α2b and ribavirin. Sci Rep 2013, 3:1686.
12. Ren Z, Yan L, Zhang N, et al. The newly emerged SARS-like coronavirus HCoV-EMC also has an "Achilles' heel": current effective inhibitor targeting a 3C-like protease. Protein Cell 2013, 4:248-250.
13. Chan KH, Chan JF, Tse H, et al. Cross-reactive antibodies in convalescent SARS patients' sera against the emerging novel human coronavirus EMC (2012) by both immunofluorescent and neutralizing antibody tests. J Infect 2013, published online April 10. 10.1016/j.jinf.2013.03.015.